187 related articles for article (PubMed ID: 37619846)
21. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
[TBL] [Abstract][Full Text] [Related]
22. The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients.
Won DD; Lee JI; Lee IK; Oh ST; Jung ES; Lee SH
BMC Cancer; 2017 Jun; 17(1):403. PubMed ID: 28583095
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.
Blons H; Emile JF; Le Malicot K; Julié C; Zaanan A; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Thaler J; Bridgewater J; Nørgård-Petersen L; Van Cutsem E; Lepage C; Zawadi MA; Salazar R; Laurent-Puig P; Taieb J
Ann Oncol; 2014 Dec; 25(12):2378-2385. PubMed ID: 25294886
[TBL] [Abstract][Full Text] [Related]
24. Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer.
Seppälä TT; Böhm JP; Friman M; Lahtinen L; Väyrynen VM; Liipo TK; Ristimäki AP; Kairaluoma MV; Kellokumpu IH; Kuopio TH; Mecklin JP
Br J Cancer; 2015 Jun; 112(12):1966-75. PubMed ID: 25973534
[TBL] [Abstract][Full Text] [Related]
25. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.
Ogino S; Shima K; Meyerhardt JA; McCleary NJ; Ng K; Hollis D; Saltz LB; Mayer RJ; Schaefer P; Whittom R; Hantel A; Benson AB; Spiegelman D; Goldberg RM; Bertagnolli MM; Fuchs CS
Clin Cancer Res; 2012 Feb; 18(3):890-900. PubMed ID: 22147942
[TBL] [Abstract][Full Text] [Related]
26. The impact of molecular profile on the lymphatic spread pattern in stage III colon cancer.
Song J; Kataoka K; Yamada T; Shiozawa M; Sonoyama T; Beppu N; Ueda K; Kuriyama S; Kanazawa A; Ikeda M; Ceelen W
Cancer Sci; 2021 Apr; 112(4):1545-1555. PubMed ID: 33484192
[TBL] [Abstract][Full Text] [Related]
27. Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
Sinicrope FA; Shi Q; Allegra CJ; Smyrk TC; Thibodeau SN; Goldberg RM; Meyers JP; Pogue-Geile KL; Yothers G; Sargent DJ; Alberts SR
JAMA Oncol; 2017 Apr; 3(4):472-480. PubMed ID: 28006055
[TBL] [Abstract][Full Text] [Related]
28. Molecular Profiling Based on KRAS/BRAF Mutation, Methylation, and Microsatellite Statuses in Serrated Lesions.
Sugai T; Eizuka M; Fujita Y; Kawasaki K; Yamamoto E; Ishida K; Yamano H; Suzuki H; Matsumoto T
Dig Dis Sci; 2018 Oct; 63(10):2626-2638. PubMed ID: 29974407
[TBL] [Abstract][Full Text] [Related]
29. The Association Between Mutations in BRAF and Colorectal Cancer-Specific Survival Depends on Microsatellite Status and Tumor Stage.
Bläker H; Alwers E; Arnold A; Herpel E; Tagscherer KE; Roth W; Jansen L; Walter V; Kloor M; Chang-Claude J; Brenner H; Hoffmeister M
Clin Gastroenterol Hepatol; 2019 Feb; 17(3):455-462.e6. PubMed ID: 29660527
[TBL] [Abstract][Full Text] [Related]
30. Microsatellite and RAS/RAF Mutational Status as Prognostic Factors in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Tonello M; Baratti D; Sammartino P; Di Giorgio A; Robella M; Sassaroli C; Framarini M; Valle M; Macrì A; Graziosi L; Coccolini F; Lippolis PV; Gelmini R; Deraco M; Biacchi D; Santullo F; Vaira M; Di Lauro K; D'Acapito F; Carboni F; Giuffrè G; Donini A; Fugazzola P; Faviana P; Sorrentino L; Scapinello A; Del Bianco P; Sommariva A
Ann Surg Oncol; 2022 Jun; 29(6):3405-3417. PubMed ID: 34783946
[TBL] [Abstract][Full Text] [Related]
31. Influence of Molecular Status on Recurrence Site in Patients Treated for a Stage III Colon Cancer: a Post Hoc Analysis of the PETACC-8 Trial.
Bruzzi M; Auclin E; Lo Dico R; Voron T; Karoui M; Espin E; Cianchi F; Weitz J; Buggenhout A; Malafosse R; Denimal F; Le Malicot K; Vernerey D; Douard R; Emile JF; Lepage C; Laurent-Puig P; Taieb J
Ann Surg Oncol; 2019 Oct; 26(11):3561-3567. PubMed ID: 31209667
[TBL] [Abstract][Full Text] [Related]
32. Concurrent BRAFV600E and BRCA Mutations in MSS Metastatic Colorectal Cancer: Prevalence and Case Series of mCRC patients with prolonged OS.
Cannon TL; Randall JN; Sokol ES; Alexander SM; Wadlow RC; Winer AA; Barnett DM; Rayes DL; Nimeiri HS; McGregor KA
Cancer Treat Res Commun; 2022; 32():100569. PubMed ID: 35567913
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer.
Kadowaki S; Kakuta M; Takahashi S; Takahashi A; Arai Y; Nishimura Y; Yatsuoka T; Ooki A; Yamaguchi K; Matsuo K; Muro K; Akagi K
World J Gastroenterol; 2015 Jan; 21(4):1275-83. PubMed ID: 25632202
[TBL] [Abstract][Full Text] [Related]
34. Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing.
Cushman-Vokoun AM; Stover DG; Zhao Z; Koehler EA; Berlin JD; Vnencak-Jones CL
Clin Colorectal Cancer; 2013 Sep; 12(3):168-78. PubMed ID: 23773459
[TBL] [Abstract][Full Text] [Related]
35. The prognostic value of KRAS and BRAF in stage I-III colorectal cancer. A systematic review.
Gallo G; Sena G; Vescio G; Papandrea M; Sacco R; Trompetto M; Sammarco G
Ann Ital Chir; 2019; 90():127-137. PubMed ID: 30739887
[TBL] [Abstract][Full Text] [Related]
36. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.
Sinicrope FA; Mahoney MR; Smyrk TC; Thibodeau SN; Warren RS; Bertagnolli MM; Nelson GD; Goldberg RM; Sargent DJ; Alberts SR
J Clin Oncol; 2013 Oct; 31(29):3664-72. PubMed ID: 24019539
[TBL] [Abstract][Full Text] [Related]
37. Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147.
Gonsalves WI; Mahoney MR; Sargent DJ; Nelson GD; Alberts SR; Sinicrope FA; Goldberg RM; Limburg PJ; Thibodeau SN; Grothey A; Hubbard JM; Chan E; Nair S; Berenberg JL; McWilliams RR;
J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24925349
[TBL] [Abstract][Full Text] [Related]
38. Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy.
Murcia O; Juárez M; Rodríguez-Soler M; Hernández-Illán E; Giner-Calabuig M; Alustiza M; Egoavil C; Castillejo A; Alenda C; Barberá V; Mangas-Sanjuan C; Yuste A; Bujanda L; Clofent J; Andreu M; Castells A; Llor X; Zapater P; Jover R
PLoS One; 2018; 13(9):e0203051. PubMed ID: 30188916
[TBL] [Abstract][Full Text] [Related]
39. Chemotherapeutic effects of MEK kinase inhibitor and BRAF kinase inhibitor on
Kim KO; Park WJ; Jung Y; Lee WS
J Chemother; 2020 Dec; 32(8):437-444. PubMed ID: 33052075
[TBL] [Abstract][Full Text] [Related]
40. [Molecular analysis of sporadic colon cancer].
Hurtado C; Wielandt AM; Zárate AJ; Kronberg U; Castro M; Yamagiwa K; Ito T; Eishi Y; Contreras L; López-Köstner F
Rev Med Chil; 2015 Mar; 143(3):310-9. PubMed ID: 26005817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
